首页> 外文期刊>Journal of molecular microbiology and biotechnology: JMMB >Current Prophylactic and Therapeutic Uses of a Recombinant Lactococcus lactis Strain Secreting Biologically Active Interleukin-12
【24h】

Current Prophylactic and Therapeutic Uses of a Recombinant Lactococcus lactis Strain Secreting Biologically Active Interleukin-12

机译:重组乳酸乳球菌菌株分泌生物活性白介素12的当前预防和治疗用途。

获取原文
获取原文并翻译 | 示例
           

摘要

The noninvasive and food-grade Gram-positive bacterium Lactococcus lactis is well adapted to deliver medical proteins to the mucosal immune system. In the last decade, the potential of live recombinant lactococci to deliver such proteins to the mucosal immune system has been investigated. This approach offers several advantages over the traditional systemic injection, such as easy administration and the ability to elicit both systemic and mucosal immune responses. This paper reviews the current research and advances made with recombinant L. lactis as live vector for the in situ delivery of biologically active interleukin-12, a potent pleiotropic cytokine with adjuvant properties when co-delivered with vaccinal antigens, at mucosal surfaces. Three well-illustrated examples demonstrate the high potential of interleukin-12-secreting lactococci strains for future prophylactic and therapeutic uses.
机译:非侵入性食品级革兰氏阳性细菌乳酸乳球菌非常适合将医学蛋白质输送至粘膜免疫系统。在最近的十年中,已经研究了活的重组乳球菌将这种蛋白质递送至粘膜免疫系统的潜力。与传统的全身注射相比,该方法具有多个优势,例如易于管理以及引发全身和粘膜免疫反应的能力。本文综述了以重组乳酸乳球菌为活载体在粘膜表面原位递送生物活性白细胞介素12(一种与疫苗抗原共同递送时具有佐剂性质的有效多效细胞因子)的活载体的研究进展。三个充分说明的实例证明分泌白介素12的乳酸球菌菌株在未来的预防和治疗用途中具有很高的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号